Avantis適度配置主動型ETF AVMA 深 滬
已收盤 05-08 16:00:00 美东时间
72.2834
+0.443
+0.62%
華盛通- 最 高72.48
- 今 開72.242
- 成交量 9109股
- 最 低 72.242
- 昨 收 71.84
- 總市值 6613.93万
- 52周最高 72.48
- 市盈率 靜 --
- 換手率 1.00%
- 52周最低 57.5924
- 委 比 0.00%
- 總股本 91.50万
- 歷史最高 72.48
- 量 比 2.49
- 振 幅 0.33%
- 歷史最低 44.4682
- 每 手 1
- 風險率 3.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Verastem Oncology Rolls Out Its Reimagine Recurrent Low-Grade Serous Ovarian Cancer Campaign For AVMAPKI FAKZYNJA CO-PACK
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine Recurrent Low-Grade Serous
04-30 19:38
Verastem Oncology To Present Long-Term Phase 2 RAMP 201 Data On AVMAPKI FAKZYNJA In Recurrent Low-Grade Serous Ovarian Cancer At SGO 2026
Plenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trialVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to
03-18 04:45
Verastem Highlights AVMAPKI FAKZYNJA Strategy and Pipeline Risks
Verastem ( ($VSTM) ) just unveiled an update. On March 4, 2026, Verastem posted...
03-05 06:27
Verastem Projects Cash Runway Into First Half of 2027
Verastem Projects Cash Runway Into First Half of 2027 Verastem Inc. reported preliminary, unaudited net product revenues of approximately $17.5 million for the fourth quarter of 2025 and about $30.9 million for the full year 2025, reflecting the launch of AVMAPKI™ FAKZYNJA™ CO-PACK in May following
02-04 20:34
Verastem erwartet für 2025 einen Umsatz von rund 30,9 Millionen US-Dollar und eine Liquiditätsreichweite bis 2027
Verastem erwartet für 2025 einen Umsatz von rund 30,9 Millionen US-Dollar und eine Liquiditätsreichweite bis 2027 Verastem Inc. meldet für das Geschäftsjahr 2025 vorläufige, ungeprüfte Nettoproduktumsätze von rund 30,9 Millionen US-Dollar für das AVMAPKI™ FAKZYNJA™ CO-PACK, nachdem das Produkt im Ma
02-04 20:34
Verastem Inc. reports FY2025 net product revenue of USD 30.9 million
Verastem Inc. reports FY2025 net product revenue of USD 30.9 million Verastem Inc. reported preliminary, unaudited net product revenues of approximately USD 17.5 million for the fourth quarter (Q4) of 2025 and approximately USD 30.9 million for the full year (FY) 2025, following U.S. FDA approval of
02-04 20:31
Biopharma firm Verastem Oncology Q2 net loss widens
Overview Verastem Q2 2025 net product revenue reaches $2.1 mln post AVMAPKI FAKZYNJA launch Net loss for Q2 2025 widens to $25.9 mln, driven by increased expenses Company ends Q2 2025 with $164.3 mln ...
2025-08-08 05:48
Verastem Inc. Reports Q2 2025: Net Loss Widens to $25.9M, EPS at $0.39; Non-GAAP Adjusted Net Loss Increases to $41.4M, EPS at $0.63; Product Revenue Hits $2.1M in Initial Six Weeks of Launch
Verastem Oncology, a biopharmaceutical company focused on developing treatments for RAS/MAPK pathway-driven cancers, reported its financial results for the second quarter ending June 30, 2025. The com...
2025-08-08 04:23
Zoetis Inc. Unveils AI Masses: Breakthrough in Veterinary Cytology for Rapid Neoplastic Cell Detection
Zoetis Inc. has unveiled AI Masses, the latest AI-powered analysis technology incorporated into the Vetscan Imagyst® analyzer, enhancing its capabilities in veterinary diagnostics. This new feature pr...
2025-06-02 20:34
